| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
GRIN Overview
Grown Rogue International Inc., through its subsidiaries, engages in the cultivation, production, and wholesale of cannabis products in Canada and the United States.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.13 |
| 52 Week High | CA$0.10 |
| 52 Week Low | CA$0.35 |
| Beta | 0.91 |
| 1 Month Change | -25.71% |
| 3 Month Change | -35.00% |
| 1 Year Change | 8.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.17% |
Recent News & Updates
Shareholder Returns
| GRIN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -7.1% | -5.7% | 1.0% |
| 1Y | 8.3% | 0.6% | 36.8% |
Return vs Industry: GRIN exceeded the Canadian Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: GRIN underperformed the Canadian Market which returned 36.5% over the past year.
Price Volatility
| GRIN volatility | |
|---|---|
| GRIN Beta | 0.91 |
| Industry Beta | 1.85 |
| Market Beta | 1 |
Stable Share Price: GRIN is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: GRIN's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | J. Strickler | https://www.grownrogue.com |
Grown Rogue International Inc., through its subsidiaries, engages in the cultivation, production, and wholesale of cannabis products in Canada and the United States. The company offers flower products, such as indicas, sativas, and hybrids; and edibles, vape cartridges, pre-rolls, or concentrates. It sells its products directly to dispensaries.
Grown Rogue International Fundamentals Summary
| GRIN fundamental statistics | |
|---|---|
| Market Cap | US$16.48m |
| Earnings (TTM) | -US$2.47m |
| Revenue (TTM) | US$6.68m |
2.5x
P/S Ratio-6.7x
P/E RatioIs GRIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRIN income statement (TTM) | |
|---|---|
| Revenue | US$6.68m |
| Cost of Revenue | US$3.16m |
| Gross Profit | US$3.52m |
| Expenses | US$5.99m |
| Earnings | -US$2.47m |
Last Reported Earnings
Jul 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 52.66% |
| Net Profit Margin | -37.06% |
| Debt/Equity Ratio | 26.9% |
How did GRIN perform over the long term?
See historical performance and comparisonValuation
Is Grown Rogue International undervalued compared to its fair value and its price relative to the market?
3.27x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GRIN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GRIN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GRIN is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: GRIN is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GRIN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GRIN is overvalued based on its PB Ratio (3.3x) compared to the CA Pharmaceuticals industry average (2.4x).
Future Growth
How is Grown Rogue International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
46.1%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Grown Rogue International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Grown Rogue International performed over the past 5 years?
17.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GRIN is currently unprofitable.
Growing Profit Margin: GRIN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GRIN is unprofitable, but has reduced losses over the past 5 years at a rate of 17.3% per year.
Accelerating Growth: Unable to compare GRIN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRIN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).
Return on Equity
High ROE: GRIN has a negative Return on Equity (-37.65%), as it is currently unprofitable.
Financial Health
How is Grown Rogue International's financial position?
Financial Position Analysis
Short Term Liabilities: GRIN's short term assets ($4.6M) exceed its short term liabilities ($2.8M).
Long Term Liabilities: GRIN's short term assets ($4.6M) exceed its long term liabilities ($2.3M).
Debt to Equity History and Analysis
Debt Level: GRIN's debt to equity ratio (26.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if GRIN's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GRIN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GRIN has less than a year of cash runway if free cash flow continues to grow at historical rates of 21.2% each year.
Dividend
What is Grown Rogue International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GRIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GRIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GRIN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GRIN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GRIN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.3yrs
Average management tenure
CEO
J. Strickler (41 yo)
2.92yrs
Tenure
US$174,882
Compensation
Mr. J. Obie Strickler serves as President, Chief Executive Officer and Chairman at Grown Rogue International Inc. He Co-Founded Grown Rogue International Inc. He is the Director of Grown Rogue Internationa...
CEO Compensation Analysis
Compensation vs Market: J.'s total compensation ($USD174.88K) is about average for companies of similar size in the Canadian market ($USD164.62K).
Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: GRIN's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
Experienced Board: GRIN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GRIN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.9%.
Top Shareholders
Company Information
Grown Rogue International Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Grown Rogue International Inc.
- Ticker: GRIN
- Exchange: CNSX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$20.402m
- Shares outstanding: 156.94m
- Website: https://www.grownrogue.com
Location
- Grown Rogue International Inc.
- 340 Richmond Street West
- Toronto
- Ontario
- M5V 1X2
- Canada
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/26 22:44 |
| End of Day Share Price | 2021/10/26 00:00 |
| Earnings | 2021/07/31 |
| Annual Earnings | 2020/10/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.